The complexity of recognizing the potential contribution of a number of possible predictors of complex disorders is increasingly challenging with the application of large-scale single nucleotide polymorphism (SNP) typing. In the search for putative genetic factors predisposing to coronary artery restenosis following balloon angioplasty, we determined genotypes for 94 SNPs representing 62 candidate genes, in a prospectively assembled cohort of 342 cases and 437 controls. Using a customized coupled-logistic regression procedure accounting for both additive and interactive effects, we identified seven SNPs in seven genes that, together, showed a statistically significant association with restenosis incidence (P Ͻ0.0001), accounting for 11.6% of overall variance observed. Among them are candidate genes for cardiovascular pathophysiology (apolipoprotein-species and NOS), inflammatory response (TNF receptor and CD14), and cell-cycle control (p53 and p53-associated protein). Our results emphasize the need to account for complex multi-gene influences and interactions when assessing the molecular pathology of multifactorial medical entities.
INTRODUCTION
The utility of percutaneous transluminal coronary angioplasty (PTCA) is limited by a high incidence of restenosis following the procedure ('post-PTCA restenosis') 1 that occurs in 30-40% of all patients. Like most common diseases, the occurrence of coronary artery restenosis following PTCA is considered a complex multifactorial disease process. Experimental and clinical studies have implicated vascular remodeling, 2 however, the specific molecular and cellular mechanisms of the processes involved remain largely unknown. None of a large number of clinical risk factors recognized for atherosclerosis or ischemic cardiovascular disease (with the possible exception of diabetes mellitus 3 ) has been found associated with the occurrence of restenosis. To evaluate the possible effects of genetic predisposition, a number of studies focusing on single-gene variants have been carried out to date, but have remained inconclusive due to a number of limitations, including study size and design. In the absence of any known strong predictors for post-PTCA restenosis, we selected this disease entity as a test case for a more comprehensive approach, with regard to both breadth of genotyping and analytical algorithms. In a cohort of post-PTCA patients three times larger than the largest sample studied so far, 4 a panel of 94 polymorphic markers was tested from 62 'candidate' genes (representing, broadly, genes related to lipid and homocysteine metabolism, vascular tone regulation, cellmatrix adhesion and interaction, matrix integrity, inflammatory and immune responses, thrombosis/coagulation, cellular homeostasis/cytoprotection mechanisms, and cell cycle/apoptotic pathways; see Table 1 ). 
RESULTS
Baseline characteristics of the study population are shown in Table 2 . As expected, there were no significant differences between the cases (restenosis) and the controls (no
The Pharmacogenomics Journal restenosis) with regard to age, blood pressure status, plasma lipid profile, smoking status, or family history of coronary heart disease. Only diabetes mellitus was significantly more common in cases than controls ( 2 2df ϭ 6.66, P ϭ 0.011). Genotype frequencies for the 94 bi-allelic markers tested were compared by 2 analysis. The corresponding uncorrected P values are provided (http://research.bwh.harvard.edu /rdbook/SNP Table.doc). Of note, only four polymorphisms were found to attain a P-value of Ͻ0.05, and among them only one of Ͻ0.01.
Subsequently, we carried out a two-stage analysis 5 to initially select a set of influential markers, followed by modeling of gene-phenotype effects and gene-gene interactions. In what we believe is the first application of a nested bootstrap (re-sampling) procedure to genetic markers, the selection stage was carried out as follows. For each SNP, 2 was computed for a 2ϫ3 table, with case-control status and genotype as the dependent and independent variables. Simply picking a marker based on its significant 2 , however, would ignore the joint effects of all markers (each marker by itself does not have a strong effect). With the selection procedure thus based on univariate 2 values, the subselection of markers to be used for the later stages of the analysis was determined using an approach described in more detail elsewhere. 5 In brief, a statistic was calculated as the sum of the 2 values over all marker loci, where the statistical significance of this sum was evaluated by 1000 bootstrap samples taken under the null hypothesis of no association. Markers were deleted from the sum stepwise, based on ascending 2 value. At each step the significance level was re-evaluated for the remaining sum until the significance level of the sum dropped below 5%. This pre-selected a set of influential markers from the original data. To validate this pre-selection procedure, we replicated the original dataset in 499 bootstrap samples retaining the association between markers and disease status. The pre-selection procedure described above was then carried out for each of the 499 replicated samples. Thus, a potentially different set of markers was pre-selected in each sample. Markers that were pre-selected in at least 2/3 of all 500 samples were then selected for modeling. Seven marker loci were thus found (APOC3 C1100T; CBS 1278T; CD14 C(Ϫ260)T; NOS3 E298D; TP53 P72R; MDM2 NlaIV site; TNFR1 A845G).
In stage 2, modeling was carried out by logistic regression, www.nature.com/tpj a method commonly used to assess the effects of risk factors on outcome variables, but so far applied to genetic analysis only rarely, and only to small datasets. 6, 7 A sequence of backward and forward stepwise regression analyses incorporated two-way and three-way interaction effects into the model. The resulting final model contains the seven markers through linear and quadratic main effects and interaction terms that cumulatively account for 11.6% of the total phenotypic variance ( Table 3) . The overall significance level of the model is P Ͻ0.0001. All these stage 2 calculations were carried out with the commercially available S-PLUS  2000 software. Note that one marker, NOS3, occurs only through interaction with other markers, that is, its direct main effect is negligible (Table 3) .
Under the assumption that non-genetic factors contribute significantly to total variance-given that the phenotype arises in response to procedural intervention-this regression formula likely explains a substantial fraction of overall genetic variance. The fact that the only other known predictor for restenosis, diabetes mellitus, only accounted for 6.7% of the variance in the present study emphasizes the significance of our finding.
DISCUSSION
Experimental and human studies have indicated plaque retention, vaso-constrictive remodeling, thrombus formation, and neointimal proliferation as the primary effector mechanisms likely to contribute to the pathophysiology of the condition. 8 Furthermore, inflammatory and immune responses, as well as apoptotic processes have also been implicated [9] [10] [11] in the underlying disease mechanism. Our findings represent the first direct clinical-epidemiological evidence for the actual relevance of these mechanisms by highlighting molecular variants of seven genes that belong to the postulated pathogenic pathways (apolipoprotein CIII, cystathionine beta-synthase, monocyte differentiation antigen CD14, endothelial nitric oxide synthase 3, tumor suppressor protein p53, p53-associated protein, and tumor necrosis factor receptor type 1) and that we found to be significantly associated with the incidence of restenosis. In the absence of data on the functional consequences of the implicated polymorphisms, further speculation is presently not justified; however, our findings prioritize these genes, among all the ones implicated in the literature so far, as candidates for functional-genetic studies.
The present study emphasizes the importance of taking a multiplicity of potentially involved gene variants into account when studying the genetic epidemiology of common complex traits. Concomitantly, it highlights the need to apply powerful, customized analytical algorithms to the data sets thus generated. Of note, although the present findings account only for a fraction of the overall genetic variance of the trait, these results were derived from a modest number of genes, indicating the value of a candidate genedriven approach. Whereas we recognize that selecting individual markers from a large set may be due to random chance (so-called multiple testing problem), we believe that the validation procedure chosen, using 499 bootstrap replicates, will largely eliminate this problem. At the same time, these results call for a more comprehensive selection of candidate genes and their variants, or for additional approaches not restricted to the bias of pre-selected candidate genes. While the current results will have limited practical applicability, we believe they point the way towards a future feasibility of creating comprehensive risk factor panels, and their application to medical practice.
MATERIALS AND METHODS

Study Design
Between March 1995 and March 1997, 909 consecutive patients who were undergoing PTCA at the Hospital San Carlos, Universidad Complutense in Madrid, Spain, were enrolled in a comprehensive follow-up study specifying symptom-independent angiographic follow-up 6 months later. All patients gave appropriate signed informed consent for both the clinical procedures and genotype testing. A total of 779 consecutive subjects fulfilled the enrollment criteria for the present study: successful PTCA, follow-up car-
The Pharmacogenomics Journal diac catheterization, interpretable quantitative coronary angiography (QCA) measurements at baseline (prior to undergoing PTCA), immediately post-PTCA (demonstrating the initial effect of the procedure) and at follow-up cardiac catheterization 6 months later, 12, 13 and the availability of a blood sample for genotype determination. Restenosis was defined as Ͼ50% reduction in the luminal diameter at the site of previous PTCA, as compared with the immediate post-PTCA angiographic record; 342 patients were classified as cases. Of note, no intra-coronary stents were deployed in any of the 779 participants in the present investigation.
Genotype Determination
Cardiovascular disease (CVD) and inflammation/asthma linear array panels (Roche Molecular Systems, Alameda, CA, USA) A general description of the protocol 14 used has previously been reported. In brief, each DNA sample is amplified in multiplex polymerase chain reactions (PCRs) using biotinylated primers. The PCR product pool is then hybridized to the corresponding panel of sequence-specific oligonucleotide probes that have been immobilized in a linear array on nylon membrane strips. A colorimetric detection method based upon incubation with streptavidin-horseradish peroxidase conjugate of hydrogen peroxide and 3,3Ј,5,5Ј-tetramethylbenzidine as substrates was used. A total of 74 markers within 47 genes were examined (http://research.bwh/ harvard.edu/rdbook/ca16ref.htm) using this system (Table  1) .
Additional polymorphisms examined
An additional 20 polymorphisms (indicated by asterisks in Table 1 ) were assayed using previously published protocols. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] To confirm genotype assignments, the PCR procedure was performed in replicate on all samples. Scoring was carried out by two independent observers. Disagreements (Ͻ2%) were resolved by a further joint reading, and where necessary, a repeat genotyping reaction. All results were scored blinded as to case-control status.
Power Calculations
The least significant relative risk was used that we would be able to recognize in the current study, assuming 80% power, based on a univariate model of analysis, on the present sample size, an additive mode of inheritance, and an alpha error of 0.05, for rare and common allele frequencies. If the minor allele frequency is 0.01, the least significant relative risk detectable is Ͼ3.3; if the minor allele frequency is 0.50, the least significant relative risk detectable is Ͼ1.3.
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